ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

Lyon (France) and Cambridge, MA (U.S.), April 7, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in the following conferences in the month of April and engage in select one-on-one investor meetings alongside members of the senior management.

SMALLCAP EVENT- CF&B Communication – April 14-15, 2021

Gil Beyen, Chief Executive Officer, will participate in one-on-one meetings from 8am to 1pm ET (02:00pm to 07:00pm CEST). For more information about the CF&B Communication’s SMALLCAP EVENT, please refer to the CF&B website: http://small2021.midcapevents.com

Kempen & Co.  Life Sciences Conference - 2021 Thematic Virtual Series – April 28, 2021

Gil Beyen, Chief Executive Officer, Iman El-Hariry, Chief Medical Officer, and Eric Soyer Chief Financial Offier  will participate in one-on-one meetings, small group meetings and showcase sessions from 8am to 2pm ET (02:00pm to 08:00pm CEST). For more information about the Kempen & Co Life Sciences Conference Series, please refer to the Kempen conference website: https://www.kempen.com/en/securities/events/life-sciences-conference

If you are interested in arranging a one-on-one meeting, please contact your conference representative or contact Corey Davis at LifeSciAdvisors.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.